Her2 Expression in Prostatic Cancer: A Comparison With Mammary Carcinoma

No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Oct 2002Her2 Expression in Prostatic Cancer: A Comparison With Mammary Carcinoma Merce Jorda, Azorides Morales, Zeina Ghorab, Gustavo Fernandez, Mehrdad Nadji, and Norman Block Merce JordaMerce Jorda , Azorides MoralesAzorides Morales , Zeina GhorabZeina Ghorab , Gustavo FernandezGustavo Fernandez , Mehrdad NadjiMehrdad Nadji , and Norman BlockNorman Block View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)64462-XAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: There is growing interest in HER2 and its downstream signaling pathway molecules as treatment targets in human malignancies, including prostatic carcinoma. We used a standard Food and Drug Administration approved HER2 immunohistochemical kit to study HER2 expression in prostate cancer. We compared the results with those reported for mammary carcinoma. Materials and Methods: For this study we selected 216 specimens obtained from patients who underwent radical prostatectomy for primary untreated prostatic carcinoma. Immunohistochemical staining was performed using the HercepTest kit (Dako Corp., Carpinteria, California) in strict fashion according to the technical and analytical protocols outlined in the kit. Results: Of the tumors 33 (15%) were positive for HER2, including 31 (94%) that were only weakly positive (2+). Of the HER2 positive tumors 97% were Gleason grade 7 or higher. Of the 33 positive cases 22 (67%) showed only a focal positive reaction for HER2 in discrete tumor areas. Conclusions: HER2 is expressed in a minority of untreated primary prostatic carcinomas. Unlike in mammary carcinoma, HER2 positivity in prostatic cancer is usually weak in intensity and focal in distribution. While the former casts doubt on the usefulness of HER2 as a potential treatment target for most primary untreated prostatic cancer, the latter phenomenon may lead to false-negative results if the test is performed in small biopsies. Furthermore, HER2 staining of prostatic carcinoma can be technically and analytically reproducible provided that there is strict adherence to the outlined methodologies and interpretation. References 1 : C-erbB-2 oncoprotein: a potential biomarker of advanced prostate cancer. Prostate1997; 30: 195. Crossref, Google Scholar 2 : Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastatic prostate cancer. Int J Cancer1999; 84: 421. Crossref, Google Scholar 3 : A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER2/neu tyrosine kinase. Nat Med1999; 5: 280. Crossref, Google Scholar 4 : From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA1999; 96: 5458. Crossref, Medline, Google Scholar 5 : HER-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst2000; 92: 1918. Crossref, Google Scholar 6 : Interaction between protein tyrosine phosphatase and protein tyrosine kinase is involved in androgen-promoted growth of human prostate cancer cells. Oncogene2000; 19: 2664. Crossref, Google Scholar 7 : Response of prostate cancer to anti-HER-2/neu antibody in androgen-dependent and -independent human xenograft models. Cancer Res1999; 59: 4761. Google Scholar 8 : Recombinant oncotoxin AR209 (anti-P185erbB-2) diminishes human prostate carcinoma xenografts. J Urol1999; 161: 984. Link, Google Scholar 9 : Tyrosine kinase inhibitors and signal transduction modulators: rationale and current status as chemopreventive agents for prostate cancer. Urology2001; 57: 77. Crossref, Google Scholar 10 : HER2 in prostate cancer—a viable target or innocent bystander?. J Natl Cancer Inst2000; 92: 1866. Crossref, Google Scholar 11 : Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma. Cancer1997; 79: 2162. Crossref, Google Scholar 12 : Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA1992; 89: 4285. Crossref, Medline, Google Scholar 13 : Her2/neu and breast cancer. Diag Molec Pathol2001; 10: 139. Crossref, Google Scholar 14 : Cell proliferation, apoptosis, oncogene, and tumor suppressor gene status in adenosis with comparison to benign prostatic hyperplasia, prostatic intraepithelial neoplasia, and cancer. Hum Pathol1999; 30: 1077. Crossref, Google Scholar 15 : Monoclonality in normal epithelium and in hyperplastic and neoplastic lesions of the breast. J Pathol2001; 193: 27. Crossref, Google Scholar 16 : Cytogenetic heterogeneity and histologic tumor growth patterns in prostatic cancer. Cytometry1995; 21: 84. Crossref, Google Scholar 17 : Elevated serum levels of p105 (erbB-2) in patients with advanced-stage prostatic adenocarcinoma. Int J Cancer1996; 69: 398. Crossref, Google Scholar From the Departments of Pathology, Medical Oncology and Urology, University of Miami-Jackson Memorial Medical Center, Miami, Florida© 2002 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited by Magdi M. Salih (2021) An Association Between Human Epidermal Growth Factor Receptor 2 and Prostate CancerAnnals of Cancer Research and Therapy, 10.4993/acrt.29.17, VOL. 29, NO. 1, (17-21), Online publication date: 8-Jan-2021. Day K, Hiles G, Kozminsky M, Dawsey S, Paul A, Broses L, Shah R, Kunja L, Hall C, Palanisamy N, Daignault-Newton S, El-Sawy L, Wilson S, Chou A, Ignatoski K, Keller E, Thomas D, Nagrath S, Morgan T and Day M (2017) HER2 and EGFR Overexpression Support Metastatic Progression of Prostate Cancer to BoneCancer Research, 10.1158/0008-5472.CAN-16-1656, VOL. 77, NO. 1, (74-85), Online publication date: 1-Jan-2017. Koh B, Li X, Zhang B, Yuan B, Lin Y, Antaris A, Wan H, Gong M, Yang J, Zhang X, Liang Y and Dai H (2015) Visible to Near-Infrared Fluorescence Enhanced Cellular Imaging on Plasmonic Gold ChipsSmall, 10.1002/smll.201502182, VOL. 12, NO. 4, (457-465), Online publication date: 1-Jan-2016. Ng H, Lu A, Lin G, Qin L and Yang Z (2014) The Potential of Liposomes with Carbonic Anhydrase IX to Deliver Anticancer Ingredients to Cancer Cells in VivoInternational Journal of Molecular Sciences, 10.3390/ijms16010230, VOL. 16, NO. 1, (230-255) Altai M, Perols A, Karlström A, Sandström M, Boschetti F, Orlova A and Tolmachev V (2012) Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with 111In using a maleimido derivative of NODAGANuclear Medicine and Biology, 10.1016/j.nucmedbio.2011.10.013, VOL. 39, NO. 4, (518-529), Online publication date: 1-May-2012. Ahmad I, Patel R, Singh L, Nixon C, Seywright M, Barnetson R, Brunton V, Muller W, Edwards J, Sansom O and Leung H (2011) HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancerProceedings of the National Academy of Sciences, 10.1073/pnas.1101263108, VOL. 108, NO. 39, (16392-16397), Online publication date: 27-Sep-2011. Papathanassiu A, MacDonald N, Emlet D and Vu H (2010) Antitumor activity of efrapeptins, alone or in combination with 2-deoxyglucose, in breast cancer in vitro and in vivoCell Stress and Chaperones, 10.1007/s12192-010-0231-9, VOL. 16, NO. 2, (181-193), Online publication date: 1-Mar-2011. Minner S, Jessen B, Stiedenroth L, Burandt E, Köllermann J, Mirlacher M, Erbersdobler A, Eichelberg C, Fisch M, Brümmendorf T, Bokemeyer C, Simon R, Steuber T, Graefen M, Huland H, Sauter G and Schlomm T (2010) Low Level Her2 Overexpression Is Associated with Rapid Tumor Cell Proliferation and Poor Prognosis in Prostate CancerClinical Cancer Research, 10.1158/1078-0432.CCR-09-2546, VOL. 16, NO. 5, (1553-1560), Online publication date: 1-Mar-2010. Festuccia C, Gravina G, Muzi P, Millimaggi D, Dolo V, Vicentini C, Ficorella C, Ricevuto E and Bologna M (2008) Her2 crosstalks with TrkA in a subset of prostate cancer cells: Rationale for a guided dual treatmentThe Prostate, 10.1002/pros.20884, VOL. 69, NO. 4, (337-345), Online publication date: 1-Mar-2009. Dai B, Kong Y, Ye D, Ma C, Zhou X and Yao X (2008) Human epidermal growth factor receptor type 2 protein expression in Chinese metastatic prostate cancer patients correlates with cancer specific survival and increases after exposure to hormonal therapyAsian Journal of Andrology, 10.1111/j.1745-7262.2008.00433.x, VOL. 10, NO. 5, (701-709), Online publication date: 1-Sep-2008. van der Poel H (2007) Molecular markers in the diagnosis of prostate cancerCritical Reviews in Oncology/Hematology, 10.1016/j.critrevonc.2006.07.003, VOL. 61, NO. 2, (104-139), Online publication date: 1-Feb-2007. (2006) Prostate Cancer Wiley Handbook of Current and Emerging Drug Therapies, 10.1002/9780470041000.cedt015, Online publication date: 13-Oct-2006. Li Z, Szabolcs M, Terwilliger J and Efstratiadis A (2006) Prostatic intraepithelial neoplasia and adenocarcinoma in mice expressing a probasin- Neu oncogenic transgeneCarcinogenesis, 10.1093/carcin/bgi324, VOL. 27, NO. 5, (1054-1067), Online publication date: 1-May-2006. Fromont G, Chene L, Vidaud M, Vallancien G, Mangin P, Fournier G, Validire P, Latil A and Cussenot O (2004) Differential expression of 37 selected genes in hormone‐refractory prostate cancer using quantitative taqman real‐time RT‐PCRInternational Journal of Cancer, 10.1002/ijc.20704, VOL. 114, NO. 2, (174-181), Online publication date: 20-Mar-2005. Yu E and Hahn W (2005) Genetic Alterations in Prostate CancerClinical Prostate Cancer, 10.3816/CGC.2005.n.003, VOL. 3, NO. 4, (220-229), Online publication date: 1-Mar-2005. Di Lorenzo G, Autorino R, De Laurentiis M, Cindolo L, D'armiento M, Bianco A and De Placido S (2018) Her-2/Neu Receptor in Prostate Cancer Development and Progression to Androgen IndependenceTumori Journal, 10.1177/030089160409000201, VOL. 90, NO. 2, (163-170), Online publication date: 1-Mar-2004. Karayi M and Markham A (2004) Molecular biology of prostate cancerProstate Cancer and Prostatic Diseases, 10.1038/sj.pcan.4500697, VOL. 7, NO. 1, (6-20), Online publication date: 1-Mar-2004. Edwards J, Mukherjee R, Munro A, Wells A, Almushatat A and Bartlett J (2004) HER2 and COX2 expression in human prostate cancerEuropean Journal of Cancer, 10.1016/j.ejca.2003.08.010, VOL. 40, NO. 1, (50-55), Online publication date: 1-Jan-2004. Aiello A, Tamborini E, Frattini M, Perrone F, Oggionni M, Pilotti S and Pierotti M (2004) Genetic Markers in Sporadic Tumors Principles of Molecular Oncology, 10.1007/978-1-59259-664-5_3, (73-150), . Roudier M, Corey E, True L, Hiagno C, Ott S and Vessella R (2004) Histological, Immunophenotypic and Histomorphometric Characterization of Prostate Cancer Bone Metastases The Biology of Skeletal Metastases, 10.1007/978-1-4419-9129-4_13, (311-339), . Di Lorenzo G, Bianco R, Tortora G and Ciardiello F (2003) Involvement of Growth Factor Receptors of the Epidermal Growth Factor Receptor Family in Prostate Cancer Development and Progression to Androgen IndependenceClinical Prostate Cancer, 10.3816/CGC.2003.n.013, VOL. 2, NO. 1, (50-57), Online publication date: 1-Jun-2003. Savinainen K and Visakorpi T (2002) 17 Expression and gene copy number alterations of her-2/neu (ERBB2) gene in prostate cancer Molecular Pathology, Colorectal Carcinoma, and Prostate Carcinoma, 10.1016/S1874-5784(02)80049-6, (449-456), . Lee P and Wang Z (2002) 13 Role of androgen receptor cofactors in prostate cancer Molecular Pathology, Colorectal Carcinoma, and Prostate Carcinoma, 10.1016/S1874-5784(02)80045-9, (409-422), . Volume 168Issue 4 Part 1October 2002Page: 1412-1414 Advertisement Copyright & Permissions© 2002 by American Urological Association, Inc.Keywordsimmunohistochemistrytumor markers, biologicalbreast neoplasmsprostateprostatic neoplasmsMetricsAuthor Information Merce Jorda More articles by this author Azorides Morales More articles by this author Zeina Ghorab More articles by this author Gustavo Fernandez More articles by this author Mehrdad Nadji More articles by this author Norman Block More articles by this author Expand All Advertisement PDF downloadLoading ...